Work

First in Human Study of SEL24/MEN1703, First in Class, Orally Available Dual PIM/FLT3 Kinase Inhibitor, in Patients with Acute Myeloid Leukemia

Year: 2019

Type: conference-abstract

Source: Blood

DOI: 10.1182/blood-2019-125878

Authors: Scott R. Solomon, Aziz Nazha, Stephen A. Strickland, Roland B. Walter, Ilaria Valimberti, Alessia Tagliavini, Paolo Mazzei, Caterina Fiesoli, Simona Scartoni, Daniela Bellarosa, Monica Binaschi, Pawel Chrom, Simone Baldini, Krzysztof Brzózka, Angela Capriati, Andrea Pellacani, Farhad Ravandi

Institutions: Cleveland Clinic, Vanderbilt University, Vanderbilt-Ingram Cancer Center, Fred Hutch Cancer Center, Menarini Group (Italy), Selvita (Poland), The University of Texas MD Anderson Cancer Center

Language: English

Topic: Acute Myeloid Leukemia Research

Subfield: Hematology

Field: Medicine

Domain: Health Sciences

SDG: Good health and well-being

Open Access status: closed

OpenAlex ID: W2989504866

Cites:

Cited by: 2

Related to: 10